Safety of Percutaneous Femoral Access for Endovascular Aortic Aneurysm Repair Through Previously Surgically Exposed or Repaired Femoral Arteries.


Journal

Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists
ISSN: 1545-1550
Titre abrégé: J Endovasc Ther
Pays: United States
ID NLM: 100896915

Informations de publication

Date de publication:
10 2023
Historique:
medline: 18 9 2023
pubmed: 7 5 2022
entrez: 6 5 2022
Statut: ppublish

Résumé

Percutaneous femoral artery access is being increasingly used in endovascular aortic repair (EVAR). The technique can be challenging in patients with previously surgically exposed or repaired femoral arteries because of excessive scar tissue. However, a successful percutaneous approach may cause less morbidity than a "re-do" open femoral approach. The aim of this study was to assess the impact of prior open surgical femoral exposure on technical success and clinical outcomes of percutaneous approach. This study retrospectively reviewed the clinical data of patients who underwent percutaneous EVAR between 2010 and 2020 at 2 major aortic centers. Patients were divided into 2 groups (with or without prior open surgical femoral access) for analysis of clinical outcomes. Only punctures with sheaths ≥12Fr were included for analysis. The access and (pre)closure techniques were similar in both institutions. Primary end points were intraoperative technical success, access-related revision, and access complications. A multivariate analysis was performed to identify determinants of conversion to open approach and femoral access complications in intact and re-do groins. A total of 632 patients underwent percutaneous (complex) EVAR: 98 had prior open surgical femoral access and 534 patients underwent de novo femoral percutaneous access. A total of 1099 femoral artery punctures were performed: 149 in re-do and 950 in intact groins. The extent of endovascular repair included 159 infrarenal, 82 thoracic, 368 fenestrated/branched, and 23 iliac branch devices. No significant differences were seen in technical success (re-do 93.3% vs intact 95.3%, p=0.311), access-related surgical revision (0.7% vs 0.6%, p=0.950), and access complications (2.7% vs 4.0%, p=0.443). For the whole group, significant predictors for access complications in multivariate analyses were main access site (odds ratio [OR] 2.39; 95% confidence interval [CI] 1.07%-5.35%; p=0.033) and increase of the procedure time per hour (OR 1.65; 95% CI 1.34%-2.04%; p<0.001), while increase in sheath-vessel ratio had a protective effect (OR 0.33; 95% CI 0.127%-0.85%; p=0.021). Surgical conversion was predicted by main access site (OR 2.32; 95% CI 1.28%-4.19%; p=0.007) and calcification of 50% to 75% of the circumference of the access vessel (OR 3.29; 95% CI 1.38%-7.86%; p=0.005). Within our population prior open surgical femoral artery exposure or repair had no negative impact on the technical success and clinical outcomes of percutaneous (complex) endovascular aortic aneurysm repair.

Identifiants

pubmed: 35514295
doi: 10.1177/15266028221092980
pmc: PMC10503241
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

730-738

Références

J Endovasc Ther. 2011 Aug;18(4):445-59
pubmed: 21861729
J Vasc Surg. 2015 Dec;62(6):1442-9.e3
pubmed: 26372191
Am J Cardiol. 2016 Oct 15;118(8):1244-1250
pubmed: 27638098
PLoS One. 2015 Apr 22;10(4):e0123739
pubmed: 25901610
J Vasc Surg. 2017 Jun;65(6):1567-1575
pubmed: 28216344
Cardiovasc Intervent Radiol. 2013 Jun;36(3):567-77
pubmed: 23483284
Cochrane Database Syst Rev. 2017 Feb 21;2:CD010185
pubmed: 28221665
J Endovasc Ther. 2009 Dec;16(6):708-13
pubmed: 19995109
Cardiovasc Intervent Radiol. 2020 Apr;43(4):547-555
pubmed: 31942649
Vasc Endovascular Surg. 2009 Feb-Mar;43(1):69-75
pubmed: 18829586
J Vasc Surg. 2014 Feb;59(2):307-14
pubmed: 24080135
J Endovasc Ther. 2013 Jun;20(3):350-5
pubmed: 23731308
J Vasc Surg. 2020 May;71(5):1503-1514
pubmed: 31727462
Eur J Vasc Endovasc Surg. 2017 Jul;54(1):104-115
pubmed: 28438400
J Vasc Surg. 2016 Oct;64(4):896-901
pubmed: 27237404
J Vasc Surg. 2021 Jan;73(1):81-91
pubmed: 32442603
J Vasc Surg. 2019 Oct;70(4):1254-1262.e1
pubmed: 30852039
Eur J Vasc Endovasc Surg. 2019 Oct;58(4):615-622
pubmed: 31500989
J Vasc Surg. 2013 Nov;58(5):1208-12
pubmed: 23830310
J Vasc Surg. 2014 Jun;59(6):1512-7
pubmed: 24560865
J Vasc Surg. 2014 May;59(5):1181-93
pubmed: 24440678
J Vasc Surg. 2018 Jun;67(6):1690-1697.e1
pubmed: 29290495
Semin Vasc Surg. 2015 Sep-Dec;28(3-4):201-7
pubmed: 27113288
Vascular. 2017 Aug;25(4):396-401
pubmed: 28068871

Auteurs

Max M Meertens (MM)

Department of Vascular Surgery, Maastricht University Medical Center, Maastricht, The Netherlands.
European Vascular Center Aachen-Maastricht, Aachen, Germany.

Emanuel R Tenorio (ER)

Division of Vascular and Endovascular Surgery, University of Texas Health Science, Houston, TX, USA.

Charlotte C Lemmens (CC)

Department of Vascular Surgery, Maastricht University Medical Center, Maastricht, The Netherlands.
European Vascular Center Aachen-Maastricht, Aachen, Germany.

Giulianna B Marcondes (GB)

Division of Vascular and Endovascular Surgery, University of Texas Health Science, Houston, TX, USA.

Guilherme B B Lima (GBB)

Division of Vascular and Endovascular Surgery, University of Texas Health Science, Houston, TX, USA.

Geert Willem H Schurink (GWH)

Department of Vascular Surgery, Maastricht University Medical Center, Maastricht, The Netherlands.
European Vascular Center Aachen-Maastricht, Aachen, Germany.

Bernardo C Mendes (BC)

Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, MN, USA.

Gustavo S Oderich (GS)

Division of Vascular and Endovascular Surgery, University of Texas Health Science, Houston, TX, USA.

Barend M E Mees (BME)

Department of Vascular Surgery, Maastricht University Medical Center, Maastricht, The Netherlands.
European Vascular Center Aachen-Maastricht, Aachen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH